News
01-11-2011, 07:10 AM
Several major health insurers say they will continue paying for Genentech's Avastin for the treatment of breast cancer, based on a recommendation from the National Comprehensive Cancer Network, Bloomberg Businessweek reports (Larkin, Bloomberg Businessweek, 1/10)...
More... (http://mnt.to/f/3PRJ)
More... (http://mnt.to/f/3PRJ)